All In Biotech

Drug Trial Radar · NCT06949033

Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 668 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

668

Planned (sponsor's estimate)

Start

May 15, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Zuoyi JiaoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to investigate the efficacy and safety of neoadjuvant cadonilimab in combination with perioperative SOX chemotherapy, compared to perioperative SOX chemotherapy alone, in patients with diffuse or mixed-type locally advanced gastric or gastroesophageal junction adenocarcinoma. The main questions it seeks to answer are: 1. Is neoadjuvant cadonilimab plus SOX chemotherapy superior to neoadjuvant placebo plus SOX chemotherapy in terms of the pathological complete response (pCR) rate at the time of surgery? 2. To evaluate and compare the 3-year OS rate in patients receiving neoadjuvant cadonilimab plus SOX chemotherapy versus patients receiving placebo plus neoadjuvant SOX chemotherapy regimen. Participants will be divided into two groups: 1. Experimental group: Participants will receive intravenous cadonilimab (10 mg/kg) in combination with the SOX regimen (oxaliplatin 130 mg/m² and S-1, with the initial dose determined based on body surface area). 2. Control group: Participants will receive a placebo in combination with the SOX regimen. After completing 3-4 cycles of treatment, patients in both the experimental and control groups will undergo radical surgery with D2 or D2+ lymphadenectomy. Following surgery, patients will receive 4 cycles of adjuvant SOX chemotherapy at 70% of the standard dosage, administered every 21 days, starting within 3-6 weeks post-surgery.

Conditions

  • Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])
  • Neoadjuvant Therapy
  • Adjuvant Chemotherapy
  • pCR Rate
  • MPR
  • ORR,OS,PFS

Interventions

  • Neoadjuvant cadonilimab combined with perioperative SOXDrug

    Cadonilimab: 10 mg/kg, iv, day 1 of every 3 weeks Oxaliplatin: 130 mg/m², iv, day 1 of every 3 weeks S1: 40-60 mg/m², po, day 1-14 of every 3 weeks (BSA \< 1.25 m², 40 mg \* 2/day, 1.25 m² ≤ BSA \< 1.5 m², 50 mg \* 2/day, BSA ≥ 1.5 m², 60 mg \* 2/day)

  • Neoadjuvant placebo plus perioperative SOXDrug

    Placebo: iv, day 1 of every 3 weeks Oxaliplatin: 130 mg/m², iv, day 1 of every 3 weeks S1: 40-60 mg/m², po, day 1-14 of every 3 weeks (BSA \< 1.25 m², 40 mg \* 2/day, 1.25 m² ≤ BSA \< 1.5 m², 50 mg \* 2/day, BSA ≥ 1.5 m², 60 mg \* 2/day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological complete response (pCR) rateTime frame: From enrollment to surgical treatment, it is expected to require 4 months.
  2. 3-year survival rate (3-year OS rate)Time frame: 3 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Gansu Provincial Hospital

    Lanzhou, Gansu, China · Recruiting

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China · Recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China · Recruiting

  • The Gastrointestinal Surgery Department, Sun Yat-sen University Cancer Center Gansu Hospital

    Lanzhou, Gansu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.